Register
Login:
Share:
Email Facebook Twitter

SAR Share Chat - RSS Feed

Sareum Share Chat (SAR)



Share Price: 0.45Bid: 0.40Ask: 0.50Change: 0.025 (+5.88%)Riser - Sareum
Spread: 0.10Spread as %: 25.00%Open: 0.425High: 0.45Low: 0.425Yesterday’s Close: 0.425


Share Discussion for Sareum (SAR)


Thread ViewThread View
Please Login or Register to post messages
Posts per page:


johnygreenfeet
Posts: 1,051
Off Topic
Opinion:No Opinion
Price:0.60
View Thread (2)
fork
4 Jun '14
is fork back
 
maytheforcework
Posts: 3,666
Off Topic
Opinion:No Opinion
Price:0.60
China
4 Jun '14
Rules for trials are probably for foreign companies and not for internal companies, so the deal we have, looks to be very exciting. They have the ability to fast track this. Thats probably why we are getting noticed. The underlying feel here is explosive.
BOOKMAN
Posts: 1,045
Off Topic
Opinion:No Opinion
Price:0.60
december 2013
4 Jun '14
Hopkirk
Posts: 1,159
Off Topic
Opinion:No Opinion
Price:0.60
Stach
4 Jun '14
Welcome back. Here is the approval process for starting clinical trials in China...

http://eng.sfda.gov.cn/WS03/CL0769/61659.html

From what i can work out, yes they can be done quicker once approval to start is granted but that approvals process (note the no of days each step takes) is longer than UK / EU or US time scales. But I'd appreciate your thoughts

GLA
ozzie43
Posts: 1,044
Observation
Opinion:No Opinion
Price:0.60
TYK2
4 Jun '14
So, basically we have found that this works well against psoriasis via oral use. First oral is easier and cheaper and psoriasis is a very common issue - therefore a good market globally.

Next, the comment as follows "Research into JAK1 has been the subject of considerable scientific interest of late and has resulted in several valuable clinical stage licensing deals." Followed by the statement that SAR will be publishing these findings in literature and at conferences in 2014. And these are already subject of patent applications in 2013.

Pieces falling into place for a licensing deal on this? We've all been so focussed on cancer products, but I wonder whether this one might be the more immediate product to capture wider attention?
BOOKMAN
Posts: 1,045
Off Topic
Opinion:No Opinion
Price:0.63
what the bleep do i know
4 Jun '14
I've only been here since 2011 this share has risen before because someone said we had a deal with astrazeneca,then that poster who ramped and ramped this share and it rose for no reason......got deleted then came back under another name ....they all rose for a reason SO WHY HAS IT RISEN NOW THEN DAAAAAM

take off your sunglasses something is brewing news will come in a week then the floodgates will open IM SURE
50sBoy
Posts: 330
Off Topic
Opinion:No Opinion
Price:0.63
sadoldgit
4 Jun '14
Thanks for taking the time to reply yesterday, i see what you mean now with the spread., appreciated.
Good luck to you and your investments also
ozzie43
Posts: 1,044
Observation
Opinion:No Opinion
Price:0.63
Don't forget TYK2....
4 Jun '14
Just be re-reading earlier RNS from Feb this year. This bit got me thinking a bit:

Auto-immune diseases and inflammatory disorders - TYK2+JAK1

Our auto-immune diseases programme is conducted in collaboration with SRI International (SRI), following the agreement announced in April 2013. The disease biology expertise at SRI has focused on disease models that demonstrate how programme compounds are able to block TYK2 dependent signalling.

Steady progress has been made since our last update. In a psoriasis disease model established at SRI, oral administration of the lead molecules leads to a significant reduction in the scaling and redness associated with the disease. Furthermore, the levels of many of the cytokines (signalling molecules) and other proteins thought to be responsible for the symptoms of psoriasis, were shown to be reduced by the addition of programme compounds. In a "rapid efficacy" model also established at SRI, levels of interferon-gamma, a cytokine involved in a number of autoimmune and inflammatory diseases, were shown to be reduced following oral administration of our lead compounds. This model allows us to rapidly screen compounds for biological activity before progressing them into more resource-intensive disease models.

These studies have also indicated that certain of our lead compounds are producing this effect via a combination of TYK2 and JAK1 inhibition. JAK1, like TYK2, is another member of the JAK family of kinases, and is essential for signalling by a number of cytokines also involved in psoriasis, as well as inflammatory bowel disease and rheumatoid arthritis. Our compounds will be tested on models of these diseases in due course. Research into JAK1 has been the subject of considerable scientific interest of late and has resulted in several valuable clinical stage licensing deals.

We are planning to publish the results of our studies in scientific literature and present them at conferences during 2014. An additional patent application protecting programme compounds was published in September 2013.
Stach
Posts: 4,935
Observation
Opinion:No Opinion
Price:0.63
Hello to All,who held for so long!
4 Jun '14
The-Oracle's remark not to be sniffed at- Tim did it before! On a brighter note,the chinese would only need six months to assess if FLT-3 obtained via SAR,has worked in their leukaemic patients or not.They could easily also have been simultaneously testing it against the competitor FLT-3 Inhibitor such as one obtained from Cephalon(USA).I am not sure about their Regulations but convinced that they are far more flexible than those in Europe and the USA.Stach
The-Oracle
Posts: 143
Off Topic
Opinion:No Opinion
Price:0.63
lol
4 Jun '14
You all reason as if we haven't been here before. Sareum could rise to 1.50 today and Tim will show his face and say no reason for rise. And this is Sar might I remind people fluctuations are the norm. Until hardcore rns shows up.



Share Trading BrochureRequest your Free brochures on share dealing, spread betting and CFDs

Sign up for Live Prices
Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.